HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,005-2,016 of 4,505
Drug study icon
CompletedNCT01451164

A Dose-finding study of OPC-34712 in people with Schizophrenia

What is this study about?

Researchers compared OPC-34712 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

In Kanto Region
SchizophreniaMedication studyAges 18–65
Countries
Japan
Sponsor
Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
Device study icon
CompletedNCT00168311

Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation in the Treatment of Negative Symptoms for schizophrenia

Official study title

A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magentic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia and Related Disorders

This study has finished and is no longer accepting participants.

In Melbourne
SchizophreniaDevice studyAges 18–70
Countries
Australia
Sponsor
The Alfred
Drug study icon
CompletedNCT00518323

Safety and Efficacy of Paliperidone Extended Release (ER) for schizophrenia

What is this study about?

Researchers compared Paliperidone ER and placebo to find out how the approaches affected psychotic symptoms in young people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Cerritos
SchizophreniaMedication studyAges 12–17
Countries
United States, India, Romania, + 2 others
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
TerminatedNCT02088060

Cannabidiol for Schizophrenia

Official study title

A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients

This study ended early.

Multiple locations, including Glostrup Municipality
SchizophreniaMedication studyAges 18–65
Countries
Denmark, Germany
Sponsor
Central Institute of Mental Health, Mannheim
Drug study icon
CompletedNCT02669758

A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

What is this study about?

Researchers studied ALKS 3831, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–70
Countries
United States, Bulgaria, Serbia, + 1 other
Sponsor
Alkermes, Inc.
Drug study icon
CompletedNCT01626456

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

What is this study about?

Researchers compared ALKS 9072, Low and ALKS 9072, High, tracking side effects to assess long-term safety in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–70
Countries
United States, Bulgaria, Malaysia, + 5 others
Sponsor
Alkermes, Inc.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.